Clinical Trials Logo
  1. Home
  2. Chronic HBV Infection
  3. NCT06029634

Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients

Chronic HBV Infection Clinical Trial

Official title:
Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients

Clinical Trial Summary

The immune mechanism of the nucleos(t)ide analogs (NAs) in inhibiting HBV replication effectively while having a low sustained virus control rate after drug withdrawal is unclear. B cell immunity and antibody response are the keys to prevent HBV reinfection and keep the virus under control. T-bet+ B, which can be regulated by IL-21, is a newly discovered major effector B cell in protection of pathogens and it is a main subtype of HBsAg-specific B cells. Thus, we suspect that T-bet+ B may play a role in ongoing controlling of the virus after withdraw of NAs in CHB patient. Based on our previous studies on CHB immunity, we use the RNAseq analyse, flow cytometry, and Elispot assay to analyze the frequency, function, and phenotype of B cells in CHB patients with different profiles after withdraw of NAs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06029634
Study type Observational
Source Changhai Hospital
Contact
Status Completed
Phase
Start date July 1, 2020
Completion date August 20, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT04470388 - A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment Phase 1
Completed NCT05019040 - Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients Phase 1/Phase 2
Completed NCT01943799 - Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B Phase 2
Recruiting NCT05792761 - A Study on Antiviral Treatment of Chronic Hepatitis B in Children N/A
Completed NCT05468060 - Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects Phase 1
Completed NCT04008004 - A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2) Phase 1
Active, not recruiting NCT05734807 - A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia Phase 2
Completed NCT04147208 - Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection Phase 2
Completed NCT03909191 - Serum HBV RNA Value on Chronic Hepatitis B Virus Infection Manage
Completed NCT03664518 - to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection Phase 2
Completed NCT05542979 - A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection Phase 1
Active, not recruiting NCT03903796 - Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection Phase 3
Completed NCT05851261 - Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects Phase 1